These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 34645283)

  • 1. Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care.
    Huttner HB; Gerner ST; Kuramatsu JB; Connolly SJ; Beyer-Westendorf J; Demchuk AM; Middeldorp S; Zotova E; Altevers J; Andersohn F; Christoph MJ; Yue P; Stross L; Schwab S
    Stroke; 2022 Feb; 53(2):532-543. PubMed ID: 34645283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Andexanet alfa versus non-specific treatments for intracerebral hemorrhage in patients taking factor Xa inhibitors - Individual patient data analysis of ANNEXA-4 and TICH-NOAC.
    Siepen BM; Polymeris A; Shoamanesh A; Connolly S; Steiner T; Poli S; Lemmens R; Goeldlin MB; Müller M; Branca M; Rauch J; Meinel T; Kaesmacher J; Z'Graggen W; Arnold M; Fischer U; Peters N; Engelter ST; Lyrer P; Seiffge D
    Int J Stroke; 2024 Jun; 19(5):506-514. PubMed ID: 38264861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
    Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI
    Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.
    Connolly SJ; Sharma M; Cohen AT; Demchuk AM; Członkowska A; Lindgren AG; Molina CA; Bereczki D; Toni D; Seiffge DJ; Tanne D; Sandset EC; Tsivgoulis G; Christensen H; Beyer-Westendorf J; Coutinho JM; Crowther M; Verhamme P; Amarenco P; Roine RO; Mikulik R; Lemmens R; Veltkamp R; Middeldorp S; Robinson TG; Milling TJ; Tedim-Cruz V; Lang W; Himmelmann A; Ladenvall P; Knutsson M; Ekholm E; Law A; Taylor A; Karyakina T; Xu L; Tsiplova K; Poli S; Kallmünzer B; Gumbinger C; Shoamanesh A;
    N Engl J Med; 2024 May; 390(19):1745-1755. PubMed ID: 38749032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
    Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ;
    Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage.
    Giovino A; Shomo E; Busey KV; Case D; Brockhurst A; Concha M
    Clin Neurol Neurosurg; 2020 Aug; 195():106070. PubMed ID: 32679541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
    Maragkos GA; Nelton EB; Richter S; Stippler M
    World Neurosurg; 2020 Oct; 142():e95-e100. PubMed ID: 32561488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the Clinical Implications of Andexanet Alfa in Factor Xa Inhibitor-Associated Intracerebral Hemorrhage.
    Chuck CC; Kim D; Kalagara R; Rex N; Madsen TE; Mahmoud L; Thompson BB; Jones RN; Furie KL; Reznik ME
    Neurology; 2021 Nov; 97(21):e2054-e2064. PubMed ID: 34556569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
    Connolly SJ; Milling TJ; Eikelboom JW; Gibson CM; Curnutte JT; Gold A; Bronson MD; Lu G; Conley PB; Verhamme P; Schmidt J; Middeldorp S; Cohen AT; Beyer-Westendorf J; Albaladejo P; Lopez-Sendon J; Goodman S; Leeds J; Wiens BL; Siegal DM; Zotova E; Meeks B; Nakamya J; Lim WT; Crowther M;
    N Engl J Med; 2016 Sep; 375(12):1131-41. PubMed ID: 27573206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy.
    Demchuk AM; Yue P; Zotova E; Nakamya J; Xu L; Milling TJ; Ohara T; Goldstein JN; Middeldorp S; Verhamme P; Lopez-Sendon JL; Conley PB; Curnutte JT; Eikelboom JW; Crowther M; Connolly SJ;
    Stroke; 2021 Jun; 52(6):2096-2105. PubMed ID: 33966491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world utilization of andexanet alfa.
    Brown CS; Scott RA; Sridharan M; Rabinstein AA
    Am J Emerg Med; 2020 Apr; 38(4):810-814. PubMed ID: 31870672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
    Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
    N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.
    Connolly SJ; Crowther M; Eikelboom JW; Gibson CM; Curnutte JT; Lawrence JH; Yue P; Bronson MD; Lu G; Conley PB; Verhamme P; Schmidt J; Middeldorp S; Cohen AT; Beyer-Westendorf J; Albaladejo P; Lopez-Sendon J; Demchuk AM; Pallin DJ; Concha M; Goodman S; Leeds J; Souza S; Siegal DM; Zotova E; Meeks B; Ahmad S; Nakamya J; Milling TJ;
    N Engl J Med; 2019 Apr; 380(14):1326-1335. PubMed ID: 30730782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures.
    Bradshaw PG; Keegan SP; Droege ME; Dykes NJH; Ernst NE; Foertsch MJ; Makley AT; Mueller EW; Philpott CD; Srinivasan V; Winter JB; Goodman MD; Droege CA
    Pharmacotherapy; 2022 Oct; 42(10):780-791. PubMed ID: 36073083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding.
    Stevens VM; Trujillo TC; Kiser TH; MacLaren R; Reynolds PM; Mueller SW
    Clin Appl Thromb Hemost; 2021; 27():10760296211039020. PubMed ID: 34541920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages.
    Barra ME; Das AS; Hayes BD; Rosenthal ES; Rosovsky RP; Fuh L; Patel AB; Goldstein JN; Roberts RJ
    J Thromb Haemost; 2020 Jul; 18(7):1637-1647. PubMed ID: 32291874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Andexanet alfa for the reversal of factor Xa inhibitors.
    Favresse J; Hardy M; van Dievoet MA; Sennesael AL; Douxfils J; Samama CM; Vornicu O; Dincq AS; Lessire S; Mullier F
    Expert Opin Biol Ther; 2019 May; 19(5):387-397. PubMed ID: 30974977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity: Prespecified Subgroup Analysis of the ANNEXA-4 Study in Japan.
    Toyoda K; Arakawa S; Ezura M; Kobayashi R; Tanaka Y; Hasegawa S; Yamashiro S; Komatsu Y; Terasawa Y; Masuno T; Kobayashi H; Oikawa S; Yasaka M
    J Atheroscler Thromb; 2024 Mar; 31(3):201-213. PubMed ID: 37635060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.
    Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ
    J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
    Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K
    Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.